Molecular Therapy

Article	Citations
Promotion or inhibition? This is a question in gene editing	366
Getting the host antiviral machinery back on track: Targeting viral suppressors of RNA interference	270
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques	241
Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma	240
Reply to In vivo confusion over in vivo conversion	232
Modulation of NLRP3 inflammasomes activation contributes to improved survival and function of mesenchymal stromal cell spheroids	207
An engineered mitoCBE facilitates efficient mitochondrial DNA editing and modified mitochondrial transfer	190
From cortex to medulla: Navigating the thymic landscape of T cell education	184
RNA interference targeting lipoprotein(a): A “big hit” against “little a”?	164
Ad-justing macrophages for cancer immunotherapy	155
The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation	154
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders	151
Targeting EBV gp42 for nasopharyngeal carcinoma prevention	149
miRNAs as neuro-oncologic therapeutics: A narrative review	144
CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma	141
Response to: DNA transposon mechanisms and pathways of genotoxicity	139
Ablation of dysmorphic neurons is a safe and effective treatment for focal cortical dysplasia II	133
Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs	132
Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo	132
Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells	128
Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans	123
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations	117
The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies	116
AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities	116
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery	115

Asparagine endopeptidase protects podocytes in adriamycin-induced nephropathy by regulating actin dynamics through cleaving transgelin	109
How to democratize cell and gene therapy: A global approach	108
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection	105
Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia	104
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy	103
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy	101
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier	99
Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo	98
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial	98
A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors	97
CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia	96
Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy	90
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease	88
High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury	88
Biologics-based technologies for highly efficient and targeted RNA delivery	87
Recent progress and future challenges in structure-based protein-protein interaction prediction	86
A novel regulatory mechanism network mediated by lncRNA TUG1 that induces the impairment of spiral artery remodeling in preeclampsia	84
Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8	83
Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities	82
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors	82
IL-1Ra gene transfer potentiates BMP2-mediated bone healing by redirecting osteogenesis toward endochondral ossification	82
Enhanced fatty acid oxidation via SCD1 downregulation fuels cardiac reprogramming	82
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2	81
Low-inflammatory lipid nanoparticles facilitate safe mRNA vaccination against influenza virus infection	80
Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity	78
Molecular Therapy Family Highlights	77
Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1	74
Harnessing B19-directed CAR T cells for AAV vector administration in seropositive patients: The importance of the niche	73
Single-cell transcriptomics unveil a unique molecular profile of mesenchymal stem/stromal cell-induced myeloid-derived immune suppressor cells	72
Targeting astrocytes with in vivo gene addition: Can it rescue loss of brain myelin?	71
Quo vadis American postdoc?	71
Retraction Notice to: The YY1-HOTAIR-MMP2 Signaling Axis Controls Trophoblast Invasion at the Maternal-Fetal Interface	70
Gene editing efficiencies and hematopoietic stem cell fitness in sickle cell disease: A balancing act	70
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing	69
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy	69
SINEUP RNA rescues molecular phenotypes associated with CHD8 suppression in autism spectrum disorder model systems	67
Viral platform engineering for targeted gene delivery to human hematopoietic stem cells	66
From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells	66
Late-Breaking Abstracts I	65
Long Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension	65
ANKRD22 promotes resolution of psoriasiform skin inflammation by antagonizing NIK-mediated IL-23 production	63
Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy	62
Autologous transplantation of mitochondria/rAAV IGF-I platforms in human osteoarthritic articular chondrocytes to treat osteoarthritis	62
In vivo base editing of a pathogenic Eif2b5 variant improves vanishing white matter phenotypes in mice	62
Progress in skin gene therapy: From the inside and out	62
Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model	62
FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1	61
Response: Promise and open questions of optogenetic vision restoration by MCO	61
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency	61
Molecular Therapy’s growing influence	60

AAV delivery of full-length SYNGAP1 rescues epileptic and behavioral phenotypes in a mouse model of SYNGAP1-related disorders	59
Efficient gene delivery admitted by small metabolites specifically targeting astrocytes in the mouse brain	58
T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8	58
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis	57
Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies	57
Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina	57
METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease	57
Disease-modifying, multidimensional efficacy of putaminal CaV1.3-shRNA gene therapy in aged parkinsonism male and female macaques	57
Smoking and tetramer tryptase accelerate intervertebral disc degeneration by inducing METTL14-mediated DIXDC1 m6 modification	56
Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain	55
Mucosal-associated invariant T cells for cancer immunotherapy	55
Fast, accurate ranking of engineered proteins by target-binding propensity using structure modeling	54
Managing allorejection in off-the-shelf CAR-engineered cell therapies	54
ASGCT 27th Annual Meeting Abstracts	54
Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial	53
Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition	53
In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors	52
Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review	52
Fluoxetine ameliorates mucopolysaccharidosis type IIIA	52
Intra-arterial transplantation of autologous mesoangioblasts in m.3243A>G mutation carriers is safe: First phase 1/2 human clinical study	52
RNA editing: Expanding the potential of RNA therapeutics	51
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP	51
Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25	51
AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes	51
RNA m6A methylation regulates dissemination of cancer cells by modulating expression and membrane localization of β-catenin	50
Structure-guided engineering of CD112 receptor variants for optimized immunotherapy	49
In this issue	49
Chimeric oncolytic adenovirus to break away from neutralizing antibodies	49
Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells	48
Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation	48
A preclinical “magic bullet” against fibrolamellar hepatocellular carcinoma?	48
The power of 2,6-diaminopurine in correcting UGA nonsense codons in CFTR mRNA	48
GDF11 Protects against Endothelial Injury and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Null Mice	48
Retraction Notice to: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer	47
A new advanced stem cell-based embryonic model: The ultimate model?	47
Essential role of CD56dimNKG2C+ NK cells trained by SARS-CoV-2 vaccines in protecting against COVID-19	46
Recent advances of engineered bacteria for therapeutic applications	46
NIIMBL’s viral vector program: A cross-gene therapy community collaboration to transform viral vector development and manufacturing	46
TIPE2 gene transfer ameliorates aging-associated osteoarthritis in a progeria mouse model by reducing inflammation and cellular senescence	46
A universal viral capsid protein based one step RNA synthesis and packaging system for rapid and efficient mRNA vaccine development	46
The Molecular Therapy family of journals continues to lead the field of gene and cell therapy	46
The curious case of AAV immunology	46
Transforming bacterial pathogens into wonder tools in cancer immunotherapy	45
Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases	45
Combined AAV-mediated specific Gjb2 expression restores hearing in DFNB1 mouse models	45
The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies	45
Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies	44
GDF11: A promising new drug target for pulmonary fibrosis?	44
Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells	44
The role of the mitochondrial protein VDAC1 in inflammatory bowel disease: a potential therapeutic target	43
Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape	43
Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies	42
Deepm5C: A deep-learning-based hybrid framework for identifying human RNA N5-methylcytosine sites using a stacking strategy	42
Reconstructed glycosylase base editors GBE2.0 with enhanced C-to-G base editing efficiency and purity	42
Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa	42
Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells	42
Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease	41
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation	41
An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis	41
Carbon monoxide-induced autophagy enhances human mesenchymal stromal cell function via paracrine actions in murine polymicrobial sepsis	41
IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors	41
AAV-mediated DMPK silencing: A defining moment in myotonic dystrophy type 1 therapeutics	41
LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis	41
A promising advance using oncolytic adenovirus to locally block tumorigenic TNF signaling	40
Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus	40
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas	40
Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal	40
In this issue	40
Harnessing engineered NK cells for refractory CD30+ lymphoma	39
In memoriam: Kenneth I. Berns, MD, PhD (1938–2024)	39
In this issue	39
Local magnetic delivery of adeno-associated virus AAV2(quad Y-F)-mediated BDNF gene therapy restores hearing after noise injury	38
AAV-mediated hepatic LPL expression ameliorates severe hypertriglyceridemia and acute pancreatitis in Gpihbp1 deficient mice and rats	38
Circulating urobilinogen augments inflammation and corticosteroid non-response in severe alcohol-induced hepatitis	38
Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis	38
Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection	38
Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading	37
N1-methyladenosine formation, gene regulation, biological functions, and clinical relevance	37
Second gene therapy for hemophilia B approved: More answers or questions?	37
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes	37

Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury	37
Current RNA strategies in treating cardiovascular diseases	37
Immunomodulatory effect of locoregional therapy in the tumor microenvironment	37
TNFAIP8L2 maintains hair cell function and regulates age-related hearing loss via mTORC1 signaling	37
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec	36
Light-stimulated insulin secretion from pancreatic islet-like organoids derived from human pluripotent stem cells	36
Rescue of hearing by adenine base editing in a humanized mouse model of Usher syndrome type 1F	36
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors	36
Catalase, a therapeutic target in the reversal of estrogen-mediated aging	35
Long-term reversal of chronic pain behavior in rodents through elevation of spinal agmatine	35
Cleavage-free human genome editing	35
Unlocking antigen flexibility with widened patient access: CD3FR in off-the-shelf CAR T cells	35
ROCK inhibition enhanced hepatocyte liver engraftment by retaining membrane CD59 and attenuating complement activation	35
Neuroserpin gene therapy inhibits retinal ganglion cell apoptosis and promotes functional preservation in glaucoma	35
2022 ASGCT Annual Meeting Abstracts	35
CD19xCD3 T cell engager shows therapeutic potential for refractory myasthenic syndromes	35
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy	35
Cardiac reprogramming via chromatin remodeling by CRISPR activation	35
PBAE-PEG-based lipid nanoparticles for lung cell-specific gene delivery	34
C5a-C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis	34
Intercellular transfer of miR-200c-3p impairs the angiogenic capacity of cardiac endothelial cells	34
From amputations to antibiotics: A future beyond “hacksaw” gene editing	34
Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases	33
Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization	33
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma	33
In this issue	33
An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming	33
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer	33
Dibenzazepine-Loaded Nanoparticles Induce Local Browning of White Adipose Tissue to Counteract Obesity	33
Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death	33
CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials	33
Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC	32
AAV-mediated genome editing is influenced by the formation of R-loops	32
In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein	32
Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control	32
Retraction Notice to: Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD	32
KCNN4 as a genomic determinant of cytosolic delivery by the attenuated cationic lytic peptide L17E	31
Enhancing VEGF therapy in T2D wounds with PLCγ2 epigenetic targeting	31
Nucleic acid modifications in self-nonself discrimination	31
Turning the tide in peritoneal metastases: Locoregional CAR-NK therapy primes systemic immunity in colorectal cancer	31
Gene replacement therapy for centronuclear myopathy: A breakthrough in complex genetic muscle disease	31
Repair Drive improves gene editing in the liver	31
An optimized SpCas9 high-fidelity variant for direct protein delivery	30
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies	30
Immune tolerance induction by hepatic gene transfer: First-in-human evidence	30
In utero genetic therapy: Treatment of early onset neurological disorders before they start	30
Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease	30
Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis	30
RAC1 directly phosphorylates both PKM2 and FBP1 to promote radioresistance in hepatocellular carcinoma	30
Therapeutic application of extracellular vesicle-encapsulated CC16 in acute lung injury	29
Targeted therapy for rare lung cancers: Status, challenges, and prospects	29
Cochlear transduction via cerebrospinal fluid delivery of AAV in non-human primates	29
In this issue	29
In this issue	29
Successful immunotherapy using adenovector gene therapy for the treatment of recurrent respiratory papillomatosis	29
Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells	29
Retraction Notice to: SET1A Cooperates With CUDR to Promote Liver Cancer Growth and Hepatocyte-like Stem Cell Malignant Transformation Epigenetically	29
The 13th International Oncolytic Virus Conference: Powerful payloads gain clinical momentum	29
On- and off-target effects of paired CRISPR-Cas nickase in primary human cells	29
Anti-amyloid treatment is broadly effective in neuronopathic mucopolysaccharidoses and synergizes with gene therapy in MPS-IIIA	29
LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency	29
Vision protection and robust axon regeneration in glaucoma models by membrane-associated Trk receptors	29
New hope for older SMA patients with next-generation self-complementary AAV gene therapy	28
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease	28
Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption	28
A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses	28
Self-amplifying loop of NF-κB and periostin initiated by PIEZO1 accelerates mechano-induced senescence of nucleus pulposus cells and intervertebral disc degeneration	28
Globin vector regulatory elements are active in early hematopoietic progenitor cells	28
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition	28
In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model	28
STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney disease	28
Perinatal loss of galactosylceramidase in both oligodendrocytes and microglia is crucial for the pathogenesis of Krabbe disease in mice	28
Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trial	28
COVID-19 mRNA vaccines: Platforms and current developments	28
The future of gene therapy: Safer vectors, sharper focus	28
Critical role of TPRN rings in the stereocilia for hearing	27
Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcγRIIb binding	27
In this issue	27
Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina	27
Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery	27
The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs	27
In this issue	27
Celebrating 25 years of Molecular Therapy	27
PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer	27
IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism	27
In this issue	27
TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8+ T cells via lysosome-dependent degradation of TCF-1	27
A sophisticated approach to targeting TERT activity in DLBCL	26
Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells	26
Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates	26
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells	26
Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells	26
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies	26
Osteoarthritis gene therapy: Expanding the scope of genetic therapies	26
Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy	26